22 Rue Garnier
Neuilly Sur Seine
188 articles about Servier
Servier to Acquire Agios Pharmaceuticals' Oncology Business
- Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 Billion plus royalties - Includes Agios' marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier's strategic ambition to become a recognized and innovative player in oncology, supported by unique drug discovery capabilities
IQVIA and Servier Collaborate to Reinvent Clinical Development
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a collaboration with Servier, an independent global pharmaceutical company, to reinvent their R&D clinical development processes and support their long-term R&D success. Servier has ambitious plans for growth a
Servier and MBC BioLabs Announce Winner of the 2020 Servier Golden Ticket
Servier, an independent international pharmaceutical company, has awarded the 2020 Servier Golden Ticket at MBC BioLabs to Telo Therapeutics, a biotechnology company focusing on working on s
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
Precision BioSciences, Inc. announced the companies have added two additional hematological cancer targets beyond CD19 and two solid tumor targets to its CAR T development and commercial license agreement.
Servier Completes the Acquisition of Symphogen
Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier's antibody center of excelle
Clinical Catch-Up: February 24-28
3/2/2020The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Cellectis and Servier Expand Collaboration on UCART19 Products
Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A
Servier Showcases Robust Presence at ASH 2019
A complete listing of this year's Servier abstracts* are available on the ASH website.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer
Ipsen and Servier announced initial safety and efficacy data from Part 1 of the Phase II/III RESILIENT study of investigational liposomal irinotecan in patients with small cell lung cancer who progressed following a first-line platinum-based regimen.
Servier Canada announces Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation
Servier Canada announces results from ENTRUST-AF PCI, the first large randomised study to evaluate the efficacy and safety of once-daily edoxaban plus a P2Y12 inhibitor against a regimen of vitamin K antagonist plus P2Y12 inhibitor and acetyl salicylic acid in atrial fibrillation patients following successful percutaneous coronary intervention.
How can you selectively target and destroy cancerous T-cells using other T-cells? This question has plagued researches hoping to apply chimeric antigen receptor (CAR) T-cell therapies to T-cell cancers.
Servier Australia & BioCurate Strike an Agreement to Collaborate and Accelerate Discoveries of New Therapeutics and Drugs
Servier and BioCurate will collaborate under the terms of a memorandum of understanding (MOU), whereby they will work together, both directly and via participation in BioCurate’s Industry and Scientific Advisory Committee, in providing advice and assessing new therapeutic candidates arising from BioCurate’s academic partners.
Ipsen and Servier Announce Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan (ONIVYDE®) as an Investigational First-line Treatment for Metastatic Pancreatic Cancer at ESMO 21st World Congress on Gastrointestinal Cancer
Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint)
Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
Servier and Galapagos NV completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.
Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology
Service agreement gives Servier access to Yposkesi’s robust production capacity
Servier Showcases Robust Presence at ASCO 2019
Servier Group and Servier Pharmaceuticals, the U.S. subsidiary of the global French pharmaceutical company, announced that data from multiple studies will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago May 31-June 4, 2019.
Exclusive: Servier Establishes First U.S. Toehold in Boston with Immediate Focus on Oncology
5/10/2019The new company celebrated the grand opening of its 100-employee Boston facility that will initially focus its efforts on developing oncology therapies.
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes
Parkinson's disease: Servier and Oncodesign join forces to investigate new line of research
Servier to be granted option to exclusively license one or several drug candidates as soon as they are approved to enter phase 1